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Summary 
Lewis rats are susceptible to several forms of experimental arthritis-induced using heat-kiUed MFobac- 
terium  tuberculosis (adjuvant arthritis, or AA), streptococcal cell walls, collagen type II, and the 
lipoidal amine CP20961.  Prior immunization with the mycobacterial 65-kD heat shock protein 
(hsp65) was reported to protect against AA, and other athritis models not using M. tuberculosis, 
via a T cell-mediated mechanism. Hsp65 shares 48% amino acid identity with mammalian hsp60, 
which is expressed at elevated levels in inflamed synovia. Several studies have reported cross-reactive 
T  cell recognition of mycobacterial hsp65  and self hsp60 in arthritic and normal individuals. 
We previously described nine major histocompatibility complex class II-restricted epitopes in 
mycobacterial hsp65 recognized by Lewis rat T  cells. Of these only one, covering the 256-270 
sequence, primed for cross-reactive T  cell responses to the corresponding region of rat hsp60. 
Here we have tested each hsp65 epitope for protective activity by immunizing rats with synthetic 
peptides. A peptide containing the 256-270  epitope, which induced cross-reactive T  cells, was 
the only one able to confer protection against AA. Similarly, administration of a T  cell line 
specific for this epitope protected against AA. Preimmunization with the 256-270  epitope in- 
duced T  cells that responded to heat-shocked syngeneic antigen-presenting cells, and also pro- 
tected against CP20961-induced arthritis, indicating that activation of T  cells recognizing an 
epitope in self hsp60 can protect against arthritis induced without mycobacteria. Therefore, in 
contrast to the accepted concept that cross-reactive T cell recognition of foreign and self antigens 
might induce aggressive autoimmune disease, we propose that cross-reactivity between bacterial 
and self hsp60 might also be used to maintain a protective self-reactive T cell population. This 
discovery might have important implications for understanding T  cell-mediated regulation of 
inflammation. 
A  the pathogenic mechanisms underlying rheumatoid ar- 
thritis (RA) remain unclear, extensive use is made of 
experimental rodent arthritis models. Lewis rats are suscep- 
tible to arthritis after administration of various arthritogenic 
preparations including heat-killed Mycobacterium  tuberculosis 
(Mt) 1 suspended in IFA (adjuvant arthritis, or AA) (1) strep- 
tococcal cell walls (SCW-arthritis) (2), collagen type II (3), 
and the lipoidal amine CP20961  (4). 
The antigenic epitope recognized by the arthritogenic T 
cell clone A2b (generated from a rat with AA) was identified 
as residues 180-188 of the 65-kD mycobacterial heat shock 
1  Abbreviations used in this paper: AA, adjuvant arthritis; DDA, dimethyl 
dioctadecyl  ammonium  bromide; hsp65, mycobacteria165-kD  heat shock 
protein; hsp60, mammalian  60-kD heat shock protein; M.256-270, syn- 
thetic peptide of mycobacterial  hsp65 256-270 sequence; Mt, heat-killed 
Mycobacterium tuberculosis; PLNC, primed lymph node cell; R.256-270, 
synthetic peptide of rat hsp60 256-270 sequence. 
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protein (hsp65) (5). After this discovery, attempts to induce 
AA by immunization with hsp65  alone failed,  but did in- 
duce a state of resistance to AA induction using Mt (5, 6) 
which was transferable to naive rats using splenic T cells (7). 
Preimmunization with hsp65 has subsequently been reported 
to confer protection against other forms of experimental ar- 
thritis induced with SCW (8), collagen type II (6), or CP20961 
(6) in Lewis  rats and pristane in mice (9). 
Mycobacterial hsp65 belongs to the hsp60 family of heat 
shock proteins that is highly conserved throughout evolu- 
tion,  and shares 48%  amino acid identity with the mam- 
malian homologue, P1 or hsp60 (10). Expression of mam- 
malian hsp60 is known to be upregulated as a physiological 
response to various stressful stimuli, and has been shown to 
be elevated in inflamed synovia of arthritis patients (11, 12) 
and rats with AA (13). There have been numerous reports 
of cross-reactive T  cell recognition of mycobacterial hsp65 
and self hsp60  (14-17).  This led to the suggestion that T 
cells specific for self hsp60 might in some way play a role 
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protective effect of preimmunization  with  hsp65  involved 
cross-reactive T  cells recognizing self hsp60  (16).  Alterna- 
tively, induction of T cell responses to mycobacterial-unique 
epitopes after hsp65 preimmunization might mediate the pro- 
tective mechanism. 
To test these hypotheses, we are undertaking a detailed anal- 
ysis of Lewis rat T cell responses to epitopes in mycobacterial 
hsp65 and rat hsp60. Previously we reported MHC class II 
(RT1.W)-restricted T  cell responses to nine hsp65 epitopes, 
and that the pattern of responsiveness differs after immuni- 
zation with hsp65 versus whole Mt (18). Here we report that 
immunization with individual synthetic peptides primes for 
T  cell responses to eight of these epitopes.  To identify the 
T cell epitopes involved in the protective effects of preimmu- 
nization with hsp65,  the effects of preimmunization  with 
peptides were studied. A peptide corresponding to hsp65(256- 
270) induced effective protection against the development of 
AA.  Peptides containing other epitopes had no effect. Ad- 
ministration of a T  cell line specific for the 256-270 epitope 
at the time of AA induction with Mt also protected against 
AA. Preimmunization with 256-270 also protected against 
CP20961-induced arthritis. The 256-270 epitope activated T 
cells that also recognized the 256-270 sequence of rat hsp60. 
Thus activation of T cells capable of responding to self hsp60 
has a protective effect in arthritis.  These findings may have 
important  implications  for vaccine development in human 
arthritic  diseases. 
Materials and Methods 
Animals.  Male inbred Lewis rats (RT11 MHC haplotype) were 
obtained from the University of Limburg (Maastricht,  The Nether- 
lands).  Rats were 5-8-wk-old at the start of each experiment. 
Antigens and Adjuvants.  Mt strain  H37Ra was obtained from 
Difco (Detroit, MI). Purified recombinant hsp65 of Mycobacterium 
bov/s  bacillus Calmette-Gu~rin  (BCG) (which is identical to M. tuber- 
culosis hsp65) was kindly provided by Dr. J.D.A. van Embden (Na- 
tional  Institute  of Public  Health  and  Environmental Hygiene, 
Bilthoven, The Netherlands). IFA (Difco) and dimethyl dioctadecyl 
ammonium bromide (DDA; Eastman Kodak, Rochester, NY) (19) 
were used as adjuvants. DDA was prepared as a 20-mg/ml suspen- 
sion in PBS and sonicated to produce a gel which was mixed 1:1 
with Ag solution before immunization.  The synthetic adjuvant 
N,N-dioctadecyl-N 1,Nl-bis[2-hydroxyethyl]propanediamine 
(CP20961,  or avridine)  (4) was obtained from Pfizer (Sandwich, 
Kent, UK). 
Peptides were prepared by automated simultaneous multiple pep- 
tide synthesis  (SMPS). The SMPS set-up was developed using a 
standard autosampler (model 221; Gilson Medical Elec. Inc., Mid- 
dleton, WI) as described previously (20). Briefly, for the concur- 
rent synthesis ofpeptides, standard Fmoc chemistry was employed 
using Pfp-activated  amino acids (Dhbt for serine and threonine) 
in a sixfold molar excess and Hobt as catalyst.  Peptides were ob- 
tained as COOH-terminal amides from 6 mg resin/peptide (0.33 
meq/g PAL  TM resin; Millipore Corp., Bedford, MA). 15-met pep- 
tides containing individual hsp65 epitopes described previously (18) 
were used. Sequences of these peptides are shown in Table 1. Ex- 
tensive use was made of the hsp65 peptide 256-270 (M.256-270) 
and the homologous peptide of rat hsp60 (R.256-270) 
Immunizations and Primed Lymph Node Populations.  Rats were 
immunized with 50/zg of synthetic peptide in PBS/DDA in each 
hind footpad (i.e., 100 #g/rat). 10 d later, draining popliteal lymph 
nodes were removed, disaggregated, washed three times, and used 
as a source of primed lymph node cells (PLNC). In some experi- 
ments, PLNC were derived as pooled inguinal and popliteal lymph 
nodes from AA rats 35-42 d after Mt immunization. In control 
experiments,  splenocytes and lymph nodes from unimmunized rats 
and PLNC from rats immunized with PBS/DDA alone were used. 
Tissue Culture Reagents.  IMDM supplemented with 5% FCS, 
2 mM I~glutamine,  100 U/ml penicillin, 100/~g/ml streptomycin 
(all from GIBCO BILL, Gaithersburg, MD) and 5  x  10 -s M 2-ME 
was used as culture medium.  Cell populations were washed  in 
IMDM without supplements. 
T Cell Proliferation Assays.  PLNC were cultured in triplicate 
in 200 #1 flat bottom microtiter wells (Costar Corp., Cambridge, 
MA) at 2  x  10  s cells per well with or without antigen. PLNC 
were tested for responsiveness to individual peptides  and hsp65 at 
20/zg/mL Con A (2/~g/ml) was used as a positive control for T 
cell proliferation. Cultures were incubated for 96 h at 37~  in a 
humidified atmosphere of 5% COz. Cultures were pulsed for the 
final 16 h with [3H]TdR (Amersham International, Amersham, 
Bucks, UK, 1 #Ci/well) and TdR uptake measured using a liquid 
scintillation  B counter. Assays using T  cell lines were performed 
as above using 2  x  104 line ceUs/weU with irradiated (30 Gy) syn- 
geneic accessory cells (2  x  10  s splenocytes/well). 
Results are expressed  as mean counts per minute of triplicate 
cultures. In experiments where responses to Ag were low, responses 
were considered significant if the stimulation index (mean counts 
per minute with Ag divided by mean counts per minute without 
Ag) was greater than 2.5 and Student's t tests  gave p  <0.01. 
T Cell Lines.  The generation of RT1.Bl-restricted T cell lines 
with specificity for individual mycobacterial  hsp65 epitopes from 
hsp65 immunized rats has been described previously (18). Short- 
term epitope-specific T cell lines were also generated from rats im- 
munized with synthetic peptides.  Peptide-PLNC were cultured at 
5  x  106/ml in culture medium supplemented with 2% normal 
rat serum (NRS) in the presence of 10 #g/ml peptide. After 3 d, 
viable cells were harvested using a Ficoll-Isopaque gradient and cul- 
tured for a further 4 d in culture medium plus 5% FCS and 5% 
T cell growth factor (TCGF) (Con A-activated rat spleen superna- 
tant).  7 d after initial stimulation, lines  were restimulated with 
irradiated  spleen accessory cells and 10/zg/ml peptide in culture 
medium plus NRS. Lines were maintained in this 7-d restimula- 
tion cycle. 
Induction and Clinical Assessment of Experimental Arthritis.  Ar- 
thritis was induced by a single  intradermal injection in the base 
of the tail.  AA was induced with 0.5 mg Mt suspended  in  100 
#1 IFA. CP20961  arthritis was induced with 2 mg CP20961  in 
100/~1 light mineral oil (Sigma Chemical Co., St. Louis, MO). 
Rats were examined daily for clinical  signs of arthritis. Severity 
of arthritis was assessed by scoring each paw from zero to four 
based on degree of swelling, erythema, and deformity of the joints. 
Thus the maximum possible arthritis  score was  16 (3). 
Modulation of Arthritis with hsp65 Peptides and Epitope-specific T 
Cell Lines.  Synthetic peptides corresponding to eight T cell epi- 
topes present in mycobacterial hsp65 were tested for protective effects 
on arthritis development.  Rats were immunized, as described above 
for PLNC generation, with t00 ~g of individual peptide 7 d be- 
fore arthritis induction. Control rats  received PBS/DDA. 
Epitope-specific  T cell lines were also tested for protective ac- 
tivity by intravenous administration of lines at the time of arthritis 
induction. T cell lines were restimulated in vitro with irradiated 
spleen APC and specific peptide. 3 d later, T cell blasts  were har- 
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gradient to remove any contaminating APC. T cells were washed 
twice in wash medium and twice in PBS and finally suspended 
at 2.5  x  10Vml in PBS. Immediately before injection of Mt, 200 
#1 (i.e., 5  x  10  e) T  cells were injected intravenously in the tail 
vein. 
mAbs.  Anti-MHC mAbs were added to proliferation assays to 
determine the MHC restriction of T  cell line responses  to pep- 
tides.  OX6  (anti-RT1.B, class II), OX17 (anti-RT1.D, class II), 
OX18 (anti-RT1.A, class I), and UD15 (antichloramphenicol con-  86-100 
trol antibody) were used. All antibodies were mouse IgG1 and were 
added at concentrations of 5-40 #g/ml. 
FACS  | Analysis.  FACS  |  analysis was used to phenotype T cell 
lines.  Cells  were incubated  with  either  K73  (anti-a/~  TCR), 
W3/25 (anti-CD4) or OX8 (anti-CDS), all mouse IgG1 antibodies.  176-190 
Second-step staining was with FITC-conjugated goat anti-mouse 
Ig (Becton Dickinson & Co., Mountain View, CA).  Cells were 
analyzed using a FACScan  |  analyzer (Becton Dickinson & Co.). 
Results  211-225 
Immunization  with hsp6  5 Peptides Primes for Epitope-specific 
T  Cell Responses.  To determine whether immunization of 
rats with synthetic peptides could prime for T  cell reactivity 
to previously described hsp65 epitopes (18), we examined in  226-240 
vitro proliferative responses  after immunization  with  nine 
peptides, each containing individual T  cell epitopes. PLNC 
isolated 10 d after immunization were tested for responsive- 
ness to the immunizing peptide, overlapping peptides,  and  256-270 
to hsp65 (Table 1). PLNC responses were observed after im- 
munization with se'cen of the peptides. Responses were not 
seen after immunization with peptides 386-400 and 511-525. 
Bulk stimulation generated T cell lines to eight of the nine 
peptides tested (attempts  to generate a line against peptide  396-410 
386-400 were unsuccessful). These eight lines were tested for 
specificity after four in  vitro restimulations  (Table  1).  All 
responded to the immunizing peptide and, to some extent,  446-460 
to hsp65.  Also,  the lines were tested for responsiveness to 
overlapping peptides and, in all but one case, showed iden- 
tical response patterns  to T  cell lines generated previously 
against  the  same epitopes  after immunization  with whole  511-525 
hsp65. These findings indicate that T  cells activated in vivo 
by immunization  with  hsp65  or synthetic peptides recog- 
nize the same core epitopes. 
The one exception to this was the T  cell line generated 
from rats immunized with the 86-100 peptide. A T  cell line 
specific for this peptide generated from rats immunized with 
hsp65 (18) responded to peptides 86-100 and 91-105 (i.e., recog- 
nizing a core epitope of 91-100).  The T  cell line generated 
after immunization with the 86-100 peptide also responded 
to peptides  81-95 and 91-105.  This suggested  the presence 
of two T  cell populations,  one recognizing residues 86-95, 
the other recognizing residues 91-100. Interestingly, the se- 
quences of mycobacterial hsp65 and rat hsp60 covering residues 
86-95 are identical. Accordingly, the line responded to pep- 
tide  81-95  of  rat  hsp60.  Thus,  immunization  with  the 
mycobacterial hsp65  86-100 peptide, but not intact  hsp65, 
could prime for responsiveness to this epitope in self hsp60. 
Previously we demonstrated that line H.52 (generated from 
hsp65-immunized rats and recognizing epitope 256-265) also 
Table  1.  Immunization with hsp65 Peptides Primes 
for T  Cell Responses 
Response 
Immunizing  In vitro  T  cell  after hsp65 
peptide  peptide  PLNC  line  immunization* 
~m 
0  2,518  1,127 
81-95  15,296  15,785  - 
86-100  57,925  49,422  + 
91-105  1,999  18,444  + 
Rat 86-100  6,196  25,535 
0  1,784  1,255 
171-185  3,082  1,640 
176-190  57,707  31,42  + 
181-195  1,916  1,653 
180-188  7,859  23,275  + 
0  986  1,479 
206-220  645  988  - 
211-225  39,765  121,978  + 
216-230  11,117  102,341  + 
0  1,286  882 
221-235  7~381  100,306  + 
226-240  22,761  152,071  + 
231-245  1,655  862  - 
0  2,448  762 
251-265  6,391  66,063  + 
256-270  16,423  69,037  + 
261-275  2,553  646  - 
Rat  256-270  4,152  14,987  + 
0  3,399  2,095 
391-405  2,280  39,335  + 
396-410  8,477  88,916  + 
401-415  3,211  2,011 
0  1,928  1,028 
441-455  4,715  17,805  + 
446-460  22,918  38,324  + 
451-465  2,130  1,283 
0  2,804  537 
506-520  2,754  61,293  + 
511-525  3,164  129,373  + 
516-530  2,821  1,231 
Rats were immunized with synthetic peptides containing  individual hsp65 
epitopes (100 #g peptide/DDA per rat). 10 d later, PLNC were isolated 
and tested for responses to overlapping peptides (20/zg/ml shown here). 
Peptide-specific  T cell lines were generated by bulk in vitro stimulation 
of PLNC with immunizing peptide. Lines were tested for responses to 
overlapping peptides (10 #g/ml). All PLNC (except 511-525-PLNC) and 
T cell lines showed signficant responses to 20 #g/ml hsp65 (data not 
shown). Results are expressed  as mean cpm of triplicate cultures. All SEM 
were <20%. Significant responses are underlined. 
" As determined previously using T cell lines generated from hsp65- 
immunized rats (17). 
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Accordingly the M.256-270 specific T cell line derived from 
peptide immunized rats also responded to R.256-270 (Table 
1). This line also showed an increased "autoreactive" response 
to syngeneic APC that had been heat-shocked (1 h at 42~ 
before irradiation) in comparison with control APC cultured 
at 37~  (Table 2). This suggested that increased expression 
of endogenous hsp60 by APC results in presentation of this 
cross-reactive epitope in association  with MHC for T  cell 
recognition. 
Analysis of the Ability of hsp65 Peptides to Vaccinate against 
Arthritis.  To determine the epitope(s) in hsp65 responsible 
for the T cell-mediated protective effect ofpreimmunization 
with hsp65, we analyzed the effects of preimmunization with 
synthetic peptides containing individual epitopes on the de- 
velopment of AA (Fig. 1). The eight peptides which primed 
for epitope-specific T cells were tested. Rats were immunized 
with 100 #g of peptide 7 d before AA-induction with Mt. 
Preimmunization with M.256-270 resulted  in clear pro- 
tective effects against AA development. The mean maximum 
arthritis  score after M.256-270 preimmunization was 2.4 (24 
rats in five separate experiments) compared with a mean max- 
imum score of 11.5 for control rats preimmunized with PBS. 
Of the 24 rats preimmunized with M.256-270,  12 did de- 
velop clinical signs of arthritis, which were milder than those 
developed by control rats. Also, whereas control rats suffered 
permanent  joint deformities that persisted after the initial ar- 
thritis had subsided, the M.256-270-preimmunized  rats which 
Table 2.  Heat-shocked  APC Stimulate hsp65(256-270)-specific 
T Cells 
T  cell line:  P.M52  H.46 
Specificity:  256-265  226-235 
cpm 
T  cells  (no APC)  44  22 
37~  APC  (no antigen)  470  33 
Plus mycobacteria1256-270  120,744  nt 
Plus rat  256-270  18,061  nt 
Plus mycobacteria1226-240  nt  162,785 
Control peptide  28  34 
42~  APC  (no antigen)  15,960  37 
Plus mycobacteria1256-270  115,626  nt 
Plus rat  256-270  25,842  nt 
Plus mycobacteria1226-240  nt  150,887 
Control peptide  12,643  41 
T cell lines (2  x  104/weU)  were cultured with APC (2  x  10S/well) that 
had been cultured for 1 h at either 37~  or 42~  before irradiation. Cells 
were cultured with or without specific peptide as Ag (10/~g/ml). Line 
H.46, specific  for the noncross-reactive, mycobacterial hsp65-unique, epi- 
tope 226-235 was used as a control. Each line was also tested against 
a control peptide (211-225 of hsp65) as an irrelevent epitope. Results are 
expressed as mean cpm of triplicate cultures.  All SEM were <20%. 
nt, not tested. 
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Figure  1.  Modulation of AA development by preimmunization with hsp65 peptides. Rats were immunized in the hind footpads with 100 #g of 
individual synthetic peptides or PBS in DDA 7 d before AA induction using 0.5 mg Mt in 100/~1 IFA injected intradermally at the base of the tail. 
Five rats were used in each preimmunization  group. Arthritis scores were assessed daily from 8 d after Mt injection. Results of two separate experiments 
are shown (experiment  1 tested 176-190, 211-225, 226-240, and 256-270; experiment 2 tested 86-100, 396-410, 446-460, and 511-525). 
946  Self hsp60-reactive T Cells and Protection  against Arthritis developed mild AA were remarkably free of permanent defor- 
mities. Preimmunization with the other seven peptides con- 
taining hsp65  T  cell epitopes had no effect on AA. 
PLNC from preimmunized rats were tested for respon- 
siveness to hsp65 epitopes 42 d after Mt administration (Fig. 
2).  PLNC from rats preimmunized with PBS/DDA alone 
showed significant responses to peptide 176-190 (containing 
the AA-associated 180-188 epitope) but not to any other of 
the defined hsp65 epitopes. PLNC from rats preimmunized 
with individual hsp65 peptides all showed responses to the 
immunizing peptide, although the level of proliferation varied. 
Thus, whereas preimmunization with peptides 211-225 and 
446-460 induced strong responses, preimmunization with pep- 
tide M.256-270 (which protected against AA) induced mar- 
ginal PLNC responses.  Responses to peptide 176-190 were 
present in all PLNC populations (and enhanced after 176- 
190 preimmunization) with one important exception. PLNC 
from rats protected from AA by preimmunization with pep- 
tide M.256-270 showed a lack of response to 176-190. This 
suggested that M.256-270-specific T cells might have an in- 
hibitory effect on potentially arthritogenic 180-188-specific 
T cells. As 176-190 is a codominant epitope recognized after 
immunization with hsp65  (18),  we tested whether preim- 
munization with M.256-270 could inhibit responses to 176- 
190 in hsp65-PLNC. Preimmunization with M.256-270 7 d 
before immunization with hsp65 showed no significant effect 
on the response of PLNC to 176-190 compared with control 
PLNC  preimmunized with  PBS  (data  not  shown).  This 
finding suggests that the lack of responsiveness to 176-190 
in PLNC from M.256-270-protected rats was not the result 
of a T  cell-T cell suppressive  activity. Rather, we favor the 
idea that this was due to the lack of arthritis in the protected 
rats. 
A  T Cell Line Specific for the Cross-reactive 256-265 Epitope 
Protects Against AA.  Preimmunization with M.256-270 pro- 
tected against arthritis. To determine whether this activity 
was the resuh of activation of T cells specific for this epitope, 
we used epitope-specific T cell lines generated previously from 
hsp65-immunized rats (18). T  cell lines were administered 
to rats at the same time as Mt for AA induction.  In two 
experiments, administration of line H.52 recognizing the 256- 
265 epitope dearly reduced the severity of AA compared with 
control animals receiving PBS (Fig. 3). The T cell lines H.36, 
H.43, and H.46 (specific for epitopes 180-188, 216-225,  and 
226-235,  respectively) were also tested and had no effect on 
AA development. To ensure that the protective effect of line 
H.52 was not the resuh of administration of residual M.256- 
270 peptide carried over from the in vitro restimulation of 
the line, line H.46 was restimulated with specific peptide (226- 
240) in the presence of 10 #g/ml M.256-270.  Administra- 
tion of the resuhing 226-235-specific T cell blasts failed to 
protect against AA. 
Preimmunization with Peptide 256-270 also Vaccinates against 
CP20961-induced Arthritis.  The only hsp65 peptide that pro- 
tected against AA was found to be M.256-270,  which in- 
duced T cell reactivity against K.256-270. This finding sug- 
gested that the hypothesis involving self-reactive T  cells to 
account for hsp65-induced protection against arthritis might 
be correct. If so this mechanism would be expected to pro- 
tect against arthritis induced by other compounds and not 
to be dependent on the use of mycobacteria. To investigate 
this, we tested the capacity of M.256-270 to induce protec- 
tion in the CP20961-induced model. As CP20961 is a lipoidal 
amine, there was no possibility of this arthritogenic preparation 
containing  an  antigenic component with  potential  cross- 
reactivity with M.256-270.  Preimmunization with M.256- 
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Figure 2.  PLNC responses of peptide-preimmunized  AA rats. Rats were preimmunized and Mt-immunized as described in Fig. 1. PLNC (pooled 
inguinal and popliteal lymph node cells from rats used in Fig. 1) were isolated 42 d after Mt immunization and tested for responses to hsp65 peptides 
containing defined T cell epitopes (20 #g/ml shown here). All PLNC responded to hsp65 and Mt (responses were all >50,000 cpm).  All SEM were 
<20%.  (11) Medium;  (L~) 86-100;  ([])  176-190; ([]) 211-225; ([]) 226-240;  (r]) 256-270;  (E2) 396-410; (1=3) 446-460;  ([]) 511-525. 
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Figure  3.  Modulation of AA using epitope-specific 
T cell lines. Rats were administered with 5  x  106 T 
cells intravenously in PBS or PBS alone at  the time 
of AA induction (0.5 mg Mt in 100 #1 IFA injected 
intradermally at  the base of the tail).  Five rats were 
used in each group. Arthritis scores were assessed daily 
from 8 d after Mt injection. Results using lines H.46 
(specific for 226-235)  and H.52 (specific for 256-265) 
are shown. Injection of lines H.36 and H.43 (specific 
for epitopes 180-188  and 216-225, respectively) had no 
effect on AA  (data  not  shown). 
270,  but  not  a control  peptide  (hsp65  211-225)  strongly 
protected rats against CP20961-induced  arthritis (Fig. 4). Thus, 
preimmunization with M.256-270 could protect against AA 
and CP20961-induced arthritis, presumably  via a mechanism 
that is not dependent on the administration of mycobacteria 
as a component  of the arthritogenic  inoculation. 
Rat hsp60(256-270)  Fails to Vaccinate against Arthritis.  Preim- 
munization with M.256-270 provided protection against AA. 
As T cells specific for this peptide also responded to the ho- 
mologous rat peptide R.256-270,  we tested R.256-270  for 
similar protective effects (Fig. 5). In two separate experiments 
protection was observed after preimmunization with M.256- 
270,  but not with R.256-270.  An explanation for this dis- 
crepancy might be that immunization with R.256-270 does 
not prime for T cell responses.  To investigate this we gener- 
ated a peptide-specific  T cell line from R.256-270 immunized 
PLNC and compared responses of this line with those of a 
line from M.256-270-immunized  PLNC (Fig.  6). The line 
generated  against  M.256-270  responded  to peptides repre- 
senting M.256-270,  M.251-265,  and a shorter  "core" pep- 
tide  M.256-265,  and  cross-reacted  with  R.256-270  and 
(weakly) R.256-265.  In contrast, the line generated  against 
R.256-270 responded to R.256-270,  R.261-275,  and R.261- 
270,  but not to any mycobacterial  peptide. 
Thus immunization with M.256-270 primed T cells recog- 
nizing the cross-reactive  256-265 core epitope, whereas im- 
munization with R.256-270 primed for responses to the rat- 
unique 261-270 core epitope (Fig. 6 B). The R.256-270 specific 
line failed  to respond to a peptide representing  R.260-269 
(data not  shown)  indicating  that all five COOH-terminal 
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Figure  4.  Modulation of CP20961-induced  arthritis 
by preimmunization with hsp65 peptides.  Rats were 
immunized in the hind footpads with 100/~g of in- 
dividual synthetic  peptides  (211-225  or  256-270)  or 
PBS in DDA 7 d before  arthritis  induction  (2  mg 
CP20961 in 100 #1 mineral oil injected intradermally 
at  the base of the  tail).  Five rats  were used in each 
preimmunization group. Arthritis scores were assessed 
daily from 8 d after CP20961 injection. 
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Figure 5.  Preimmunization  with rat hsp60(256- 
270) fails  to protect against  AA. Rats  were  immunized 
in the hind footpads  with 100/zg of individual  syn- 
thetic peptides or PBS in DDA 7 d before  AA induc- 
tion (0.5 mg Mt in 100/zl IFA injected  intradermally 
at the base of the tail). Five rats were used in each 
preimmunization  group. Arthritis scores were assessed 
daily from 8 d after Mt injection. Preimmunization 
with a control  peptide  (hsp65 211-225) did not influence 
AA development (data not shown). 
residues of R.256-270 were essential for stimulation of this 
line.  None  of these  five residues  share  identity with the 
mycobacterial sequence  (Fig.  6 B), presumably accounting 
for the lack of responsiveness  to M.256-270. 
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Figure 6.  Immunization  with hsp65(256-270) and rat hsp60(256-270) 
primes for T cell  responses to distinct  epitopes. (/1) Rats were immunized 
in the hind footpads  with either M.256-270 or R.256-270 in DDA. 7 d 
later, PLNC  were isolated  and restimulated  in vitro  with the immunizing 
peptide. The resulting  T cell lines (line P.M52 recognizing  M.256-270, 
and line P.R57 recognizing R.256-270) were tested for responses to 
mycobacterial  and rat peptides in the presence  of irradiated  syngeneic  spleen 
APC. All SEM were <20%. (B) Comparison of mycobacterial  and rat 
256-270 sequences. The distinct  epitopes recognized  by lines P.M52 and 
P.R57 are boxed. (10). 
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Furthermore, the T cell lines generated against M.256-270 
and R.256-270 were found to have different MHC restric- 
tions. Peptide-induced proliferation of the M.256-270-specific 
line was inhibited by the OX6 anti-RT1.B mAb, whereas 
the R.256-270-specific line was inhibited by the OX17 anti- 
R.T1.D mAb (data not shown). FACS  |  analysis revealed that 
both lines  were oJ/~-TCR+CD4 + (data not shown). 
Discussion 
Vaccination with mycobacterial hsp65 protects Lewis rats 
against not only AA (5, 6), but also arthritis induced with 
SCW (8) collagen type II (6) or the lipoidal amine CP20961 
(6). T cell reactivity against hsp65 is believed to be involved 
in the protective mechanism(s) (7). Previously we character- 
ized the T cell response to hsp65 in Lewis rats and identified 
nine epitopes  recognized in  association with  the  R.T1.B  1 
MHC class II molecule (18). In this study we have analyzed 
the ability of individual T cell epitopes to influence the de- 
velopment of AA. Rats were preimmunized with synthetic 
peptides containing individual epitopes 7 d before AA in- 
duction with Mt. This approach led to a striking protective 
effect in rats preimmunized with peptide M.256-270. None 
of the other peptides tested showed any influence on AA de- 
velopment. The T cell line H.52, originally generated from 
hsp65-immunized rats and specific for epitope 256-265  also 
showed a protective effect on AA development when injected 
intravenously at the time of Mt administration. 
Our finding that preimmunization with peptide 176-190 
(containing the AA-associated 180-188 epitope) had no effect 
on AA onset is in contrast with previous reports of protec- 
tion after preimmunization with peptide 180-188 (21, 22). 
This difference might be due to the different preimmuniza- 
tion regimens adopted. We immunized once with peptide 
in the footpads 7 d before Mt immunization using DDA as 
adjuvant, whereas the previous studies immunized intraperi- toneally with Peptide in IFA three times on days -35,  -20, 
and - 5. Lymph node responses to the 176-190 epitope were 
absent  in rats protected by preimmunization with M.256- 
270. As preimmunization with M.256-270 did not influence 
lymph node cell responses to 176-190 in rats immunized with 
hsp65, we conclude that a direct suppressive activity of M.256- 
270-specific T cells on 176-190 specific (arthritogenic) T cells 
did not account for this effect. Previously we showed that 
lymph node cells from rats immunized with the AA-inducing 
protocol (Mt/IFA) did not respond to 176-190 before the de- 
velopment of clinical AA at ,o14 d (18). Therefore, we sug- 
gest that significant responses to 176-190 in polyclonal lym- 
phoid populations after Mt/IFA immunization correlate with 
development of overt AA. 
Line H.52 recognizes the 256-270 sequence of rat hsp60 
(18). Similarly, T cell lines derived from rats immunized with 
M.256-270  responded to R.256-270.  These lines  also re- 
sponded to heat-shocked APC, indicating presentation of the 
endogenous self hsp60 epitope in association with MHC class 
II for T cell recognition as a result of increased hsp60 expres- 
sion. These findings support the hypothesis that hsp65 preim- 
munization protects against arthritis by activation of T cells 
recognizing a shared epitope in rat hsp60.  This hypothesis 
does not  require  the "protective" T  cells  to  recognize a 
mycobacterial component in the joint and therefore provides 
an attractive single mechanism for explaining hsp65-induced 
resistance  to  models not  employing bacterial-derived  ar- 
thritogens. The most notable of these models in the Lewis 
rat is induced with CP20961,  a lipoidal amine with no pos- 
sible antigenic cross-reactivity with hsp65 (4). It is encouraging 
that immunization with M.256-270 also protected against 
CP20961-induced arthritis. 
Thus,  immunization with M.256-270 activated  T  cells 
responsive to R.256-270 and protected against two forms of 
arthritis induced by different arthritogens and (presumably) 
having different pathogenic mechanisms. These findings sug- 
gest strongly that the mechanism underlying the protective 
effect involves T cell recognition of the self hsp60 epitope 
expressed by APC in the inflamed joint. Raised expression 
in the joint due to cell stress during inflammation (11-13) 
would make hsp60 a reliable target antigen for regulatory 
T cell recognition controlling inflammatory responses. The 
exact nature of the regulatory mechanism activated by the 
hsp60 "alarm signal" remains to be elucidated. If the self hsp60- 
specific T cells display a TH2 pattern of cytokine secretion, 
they might be expected to have antiinflammatory effects via 
inhibitory effects of IL-IO on macrophage production of IL- 
12, and IL-4 on IFN-3, production by "auto-aggressive" TH1 
cells recognizing self antigens in the joint (23). Alternatively, 
production of TGF-3 by the regulatory cells might have an 
inhibitory effect on the autoaggressive T cell population (24). 
A further possibility is that regulatory T cells have cytotoxic 
activities on APC expressing increased hsp60 and MHC class 
II levels. CD4 + T cells capable of MHC class II-restricted 
lysis of macrophages pulsed with self hsp60 peptides have 
been isolated from healthy human donors (14) and RA pa- 
tients (17). Experiments to determine cytotoxic activity and 
cytokine profiles of M.256-270-specific T cells are in progress. 
Interestingly, preimmunization with rat 256-270 failed to 
protect against AA. T cell lines derived from rats immunized 
with M.256-270 and R.256-270 recognized two distinct epi- 
topes.  Immunization  with  M.256-270  induced  RT1.B  l- 
restricted T cells specific for the cross-reactive core epitope 
256-265.  Immunization with R.256-270 induced RT1.D  1- 
restricted T cells specific for the rat-unique core epitope 261- 
270. Thus the protective effect observed here required T cell 
recognition  of the  256-265  epitope  in  association  with 
RT1.B  1. The relatively weak responses  to R.256-270 after 
M.256-270 immunization suggest the trimolecular interac- 
tion of R.256-270, RT1.B  l, and TCR was of relatively low 
affinity. The strong proliferative responses of the R.256-270- 
specific T  cell line suggest that  the R.256-270,  RT1.D  z, 
TCR interaction might be of high affinity. The rat-unique 
R.261-270 epitope might be cryptic (i.e., not expressed with 
MHC class II after processing of endogenous hsp60 by APC 
and therefore not available for recognition by potentially pro- 
tective T cells). If so, T cells with high affinity for this epi- 
tope would not be negatively selected  in the thymus and would 
dominate the T cell response after immunization with R.256- 
270, preventing development of an effective response to the 
protective 256-265 epitope. If differing affinities of the two 
interactions result from RT1.D 1 having a higher binding 
affinity than RT1.B  1  for R.256-270, a form of "determinant 
capture" (25) could account for this effect. Analysis of the 
binding affinities of both MHC class II molecules for R.256- 
270 and M.256-270 will darify this point. Experiments testing 
whether immunization with the R.256-265 core epitope in- 
duces protective T  cells are in progress.  Thus, therapeutic 
applications  may require the use of bacterial hsp60 epitopes 
that induce relatively low affinity cross-reactive responses to 
endogenously processed self hsp60.  Any self hsp60 epitopes 
that prove strongly immunogenic  when administered as syn- 
thetic peptides may well be cryptic as high affinity responses 
to epitopes of naturally processed endogenous hsp60 would 
be controlled by normal mechanisms of thymic negative se- 
lection and peripheral tolerance. 
The aim of this study was to define the T cell epitope(s) 
involved in protection induced by whole hsp65. Our results 
provide evidence that T cells recognizing an appropriate self 
hsp60 epitope have a beneficial influence on arthritis devel- 
opment. The conventional view is that T cells with cross- 
reactivity for foreign Ag and structurally similar self Ags may 
play a role in autoimmune pathogenesis (26).  In addition, 
we now suggest that T cells with low affinity for self hsp60 
may be used as a normal Ag-specific mechanism of regulating 
inflammation. These T cells would be maintained in the pe- 
riphery through stimulation by shared epitopes in hsp60 cog- 
nates of commensal bacteria.  On this point it is noteworthy 
that Fisher rats (normally arthritis resistant) are susceptible 
to AA when raised in germ-free conditions (27), and resis- 
tance can be re-established by infection with Escherichia coli 
(28).  Also,  it has been reported that BCG treatment has 
beneficial effects in diabetes (29) and that vaccination with 
a peptide corresponding to mouse hsp60 (437-460) can pro- 
tect against diabetes in NOD mice (30). Recent evidence from 
studies in arthritis patients lend support to the idea of T cell 
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T  cell lines  generated from a patient with a short history 
of RA responded to epitopes in the highly conserved 243- 
265 region of hsp65, and one cross-reacted with the homol- 
ogous human hsp60 peptide (17). Also, juvenile chronic ar- 
thritis patients with mild oligoarticular disease of favorable 
prognosis show T cell responses to recombinant human hsp60 
(31), whereas patients with severe disease do not (Prakken, 
A. B. J., manuscript in preparation).  If these findings can 
be extended to show that patients with severe disease lack 
appropriate responses to self hsp60,  immunotherapy by vac- 
cination for T cell responsiveness to self hsp60 would be an 
attractive possibility. 
This work was supported by The Wellcome Trust, United Kingdom, and by the Netherlands Organiza- 
tion for Scientific  Research (NWO), grant 900-506-169. S. M. Anderton was supported by a Wellcome 
Trust postdoctoral research fellowship to Western Europe. 
Address correspondence to Dr. W. van Eden, Institute of Infectious Diseases and Immunology, Faculty 
of Veterinary Medicine, Postbus 80.165, 3508 TD Utrecht,  The Netherlands. 
Received for publication 27June  1994 and in revised  form  I9 October 1994. 
References 
1.  Pearson,  C.M. 1956. Development  of arthritis, periarthritis and 
periostitis in rats given adjuvant. Pro~ Soc. Exp. Biol. Med. 
91:95-101. 
2.  Cromartie, W.J., J.G. Craddock, J.H. Schwab, S.K. Anderle, 
and C. Yang. 1977. Arthritis in rats after systemic injection 
of streptococcal cells or cell walls.J. Exl~Med. 146:1585-1602. 
3.  Trentham, D.E., A.S. Townes, and A.H. Kang. 1977. Autoim- 
munity to collagen: an experimental model of  arthritis.J. Extx 
Med. 146:857-868. 
4.  Chang,  Y.-H., C.M. Pearson, and C. Abe. 1980. Adjuvant  Poly- 
arthritis IV. Induction by a synthetic adjuvant: immunologic, 
histopathologic, and other studies. Arthritis Rheum. 23:62-71. 
5.  Van Eden, W., J.E.R. Thole, R. van der Zee, A. Noordzij, 
J.D.A.  van Embden, E.J. Hensen, and I.R. Cohen.  1988. 
Cloning the mycobacterial  epitope recognized by T lympho- 
cytes in adjuvant arthritis. Nature (Lond.). 331:171-173. 
6.  Billingham, M.E.J., S. Carney, R. Butler, and M.J. Colston. 
1990. A mycobacterial heat shock protein induces antigen- 
specific suppression of adjuvant arthritis, but is not itself ar- 
thritogenic, j. Exp. Med. 171:339-344. 
7.  Hogervorst, E.J.M., J.P.A. Wagenaar,  C.J.P. Boog, R. van der 
Zee, J.D.A. van Embden, and W. van Eden. 1992. Adjuvant 
arthritis and immunity to the mycobacteria165kD heat shock 
protein. Int. Immunol. 4:719-727. 
8.  Van den Broek, M.F., E.J.M. Hogervorst, M.C.J. van Bruggen, 
W. van Eden, R. van der Zee, and W.B. van den Berg. 1989. 
Protection against streptococcal cell wall-induced arthritis by 
pretreatment with the 65-kD mycobacterial  heat shock pro- 
tein. j. Exp. Med. 170:449-466. 
9.  Thompson, S.J., G.A.W. Rook, R.J. Brealey,  R. van der Zee, 
and C.J. Elson. 1990. Autoimmune reactions to heat-shock 
proteins in pristane-induced arthritis.  Eur. J.  Immunol. 20: 
2479-2484. 
10. Jindal, S., A.K.  Dubani, B. Singh, C.B. Harley,  and R.S. Gupta. 
1989. Primary structure of a human mitochondrial protein ho- 
mologous to the bacterial and plant chaperonins and to the 
65-kilodalton mycobacterial  antigen. Mol. Cell. Biol. 9:2279- 
2283. 
11.  Karlsson-Parra, A., K. Soderstrom, M. Ferm, J. Ivanyi, R. 
951  Anderton  et al. 
Kiessling, and L. Klareskog. 1990. Presence of human heat 
shock protein (hsp) in inflamed  joints and subcutaneous  nodules 
of RA patients. Scand. J. ImmunoI. 31:283-288. 
12.  Boog,  C.J.P., E.R. de Graeff-Meeder,  M.A. Lucassen,  R. van 
der Zee, M.M.  Voorhorst-Ogink,  P.J.S. van Kooten,  H.J. 
Geuze, and W. van Eden. 1992. Two monoclonal antibodies 
generated against human hsp60 show reactivity with synovial 
membranes of patients with juvenile chronic arthritis. J. Exp. 
Med. 175:1805-1810. 
13.  Kleinau, S., K. Soderstrom, R. Kiessling,  and L.A. Klareskog. 
1991. A monoclonal antibody to the mycobacteria165  kD heat 
shock protein (ML 30) binds to cells in normal and arthritic 
joints of rats. Scand. J. Immunol. 33:195-202. 
14.  Munk, M.E., B. Schoel, S. Modrow, R.W. Karr, R.A. Young, 
and S.H.E. Kaufmann. 1989. T lymphocytes from healthy in- 
dividuals with specificity  to self-epitopes  shared  by the mycobac- 
terial and human 65-kilodalton  heat shock protein..]. Immunol. 
143:2844-2849. 
15.  Lamb,  J.R., V. Bal, P. Mendez-Samperio,  A. Mehlert, A. So, 
J. Rothbard, S. Jindal, R.A. Young, and D.B. Young. 1989. 
Stress proteins may provide a link between the immune re- 
sponse to infection  and autoimmunity. Int. Immunol. 1:191-196. 
16.  Anderton, S.M., R. van der Zee, and J.A.  Goodacre. 1993. 
Inflammation activates self hsp60-specific T cells. Eur. j. Im- 
munol. 23:33-38. 
17.  Quayle, A.J., K.B. Wilson,  S.G. Li, J.  Kjeldsen-Kragh, F. 
Oftung, T. Shinnick, M. Sioud, O. Forte, J.D. Capra, andJ.B. 
Natvig. 1992. Peptide recognition, T cell receptor usage and 
HLA restriction elements of human heat-shock protein (hsp) 
60 and mycobacterial  65-kDa hsp-reactive T cell clones from 
rheumatoid synovial fluid. Eur. J. Immunol. 22:1315-1322. 
18.  Anderton, S.M., R. van der Zee, A. Noordzij, and W. van 
Eden. 1994. Differential  mycobacteria165-kDa  heat shock pro- 
tein T cell epitope recognition after adjuvant arthritis inducing 
or protective immunization protocols.J. Immunol. 152:3656- 
3664. 
19.  Snippe, H., and C.H. Kaaieveld. 1989. The immunoadjuvant 
dimethyldioctadecyl  ammonium bromide. In Immunological 
Adjuvants and Vaccines. G. Gregoriades, A.C. Allison, and P. Post, editors, Plenum Press, New York.  47-59. 
20.  Van der lee, R., M.H.M. Wanben, T.H.A. Lots, and W. van 
Eden. 1992. Simultaneous multiple peptide synthesis  (SMPS) 
for the analysis of T  cell epitopes. J. Cell. Biochem. 16D:83. 
21.  Yang, X-D., J. Gasser, and U. Feige. 1990. Prevention of adju- 
vant arthritis in rats by a nonapeptide from the 65-kD mycobac- 
terial heat-shock protein. Clin. Exp. Immunol. 81:189-194. 
22.  Yang, X-D., J. Gasser, and U. Feige. 1992. Prevention of adju- 
vant arthritis in rats by a nonapeptide from the 65-kD mycobac- 
terial heat shock protein: specifidty and mechanism.  Clin. ExI~ 
Iramunol. 87:99-104. 
23.  Paul, W.E., and K.A. Seber. 1994. Lymphocyte responses and 
cytokines. Cell. 76:241-251. 
24.  Miller,  A., A. A1-Sabbagh, L.M.B. Santos,  M. Prabhu Das, 
and H.L. Weiner.  1993. Epitopes of myelin basic protein that 
trigger TGF-~ release after oral tolerization are distinct from 
encephalitogenic epitopes and mediate epitope-driven bystander 
suppression. J. Immunol.  151:7307-7315. 
25.  Sercarz,  E.E., P.V. Lehmann, A. Ametani, G. Benichou, A. 
Miller, and K. Moudgil. 1993. Dominance and crypticity of 
T cell antigenic determinants. Annu. Rev. Immunol. 11:729-766. 
26.  Oldstone, M.B.A. 1987. Molecular mimicry and autoimmune 
disease. Cell. 50:819-820. 
27.  Kohashi, O., J. Kutawa, K. Umehara, F. Uemura, T. Taka- 
hashi, and A. Ozawa. 1979. Susceptibility to adjuvant-induced 
arthritis among germfree, specific pathogen free and conven- 
tional rats.  Infect. Imraun. 26:791-794. 
28.  Kohashi, O., Y. Kohashi, T. Takahashi,  A. Ozawa, and N. 
Shigematsu.  1986.  Suppressive  effect of Escherichia coli on 
adjuvant-induced arthritis in germ-free rats. Arthritis Rheum. 
29:547-552. 
29.  Shehadeh, N., F. Calcinaro, B.J. Bradley, I. Bruchim, P. Vardi, 
and K.J. Lafferty. 1994. Effect of adjuvant therapy on develop- 
ment of diabetes in mouse and man. Lancet. 343:706-707. 
30.  Elias, D., T. Kesheef, O.S. Birk, R. van der lee, M.D. Walker, 
and I.K. Cohen. 1991. Vaccination against autoimmune mouse 
diabetes with a T cell epitope of the human 65-kDa heat shock 
protein. Proc Natl. Acad. Sci. USA.  88:3088-3091. 
31.  De Graeff-Meeder,  E.K., R, van der lee, G.T. Rijkers,  H.-J. 
Schuurman, W. Kuis, J.W.J.  Bijlsma, B.J.M. Zegers, and W. 
van Eden. 1991. Recognition of human 60 kD heat shock pro- 
tein by mononuclear cells from patients with juvenile chronic 
arthritis. Lancet. 337:1368-1372. 
952  Self hsp60-reactive T Cells and Protection against Arthritis 